期刊文献+

RmhTNF联合顺铂与单用顺铂胸腔注射治疗恶性胸腔积液的比较 被引量:9

Clinical observation on rmhTNF plus cisplatin compared with cisplatin alone in the treatment of malignant pleural cavity effusion
暂未订购
导出
摘要 目的研究重组改构肿瘤坏死因子(rmhTNF)+顺铂及单用顺铂治疗恶性胸腔积液的疗效及毒性反应。方法两组所有病例均先采用中心静脉管胸腔置管术,胸水引流干净后,胸腔内分别注入rmhTNF+顺铂或单用顺铂,观察两组疗效及毒性反应。结果rmhTNF+顺铂组治疗恶性胸腔积液的有效率为92.5%,单用顺铂组为80.6%;两组毒副反应发生率分别为39.6%和41.9%。结论rmhTNF+顺铂组治疗恶性胸腔积液的疗效优于单用顺铂组,而毒副反应无差别。 Objective: To study the efficacy and adverse effects of rmhTNF plus cisplatin and cisplatin alone in the treatment of malignant pleural cavity effusion. Methods: All patients diagnozed as malignant pleural cavity effusion by cytology were divided into therapy group and control group, and they were given the close drainage. When malignant pleural cavity effusion was drained mainly, rmhTNF plus cisplatin were inculcated in the therapy group while cisplatin inculcated in the control group. To observe the efficacy and adverse effects in the two groups. Results : Thirty one patients showed CR and 18 patients showed PR in the therapy group, giving an effective rate of 92.5% and a toxicity occured rate of 39.6% ; 9 patients showed CR and 16 patients showed PR in the control group, giving an effective rate of 80.6% and a toxicity occured rate of 41.9%. Conclusion: The efficacy of rmhTNF plus cisplatin group is better than cisplatin alone group. There were no significant differences in the incidence of side effects and toxic effects between the two groups.
出处 《现代肿瘤医学》 CAS 2007年第2期202-203,共2页 Journal of Modern Oncology
关键词 恶性胸腔积液 顺铂 重组肿瘤坏死因子 malignant pleural cavity effusion cisplatin rmhTNF
  • 相关文献

参考文献4

二级参考文献27

  • 1黄敏丽,孙红,丰有吉,尹德领.肿瘤坏死因子及化疗联合治疗晚期妇科恶性肿瘤的探索[J].中国肿瘤生物治疗杂志,1995,2(3):201-203. 被引量:3
  • 2[1]Lee KY, Chang W, Qiu D, et al. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem,1999,274(19)∶13451-13455.
  • 3[2]Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst,1996,88 (19)∶1383-1392.
  • 4[3]Lasek W, Giermasz A, Kuc K, et al. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer,1996,66(3)∶374-379.
  • 5[5]Chcialowski A, Targowski T, Bajera I, et al. Tumor necrosis factor-alpha--phase Ⅰ and phase Ⅱ clinical trials. Pol Merkuriusz Lek,1997,2(12)∶396-399.
  • 6[6]Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res,1998,18(5D)∶3937-3939.
  • 7[7]Fukushima T, Yamamoto M, Ikeda K, et al. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res,1998,18(5D)∶3965-3970.
  • 8Eggermont AMM, Schreffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial[J]. Clin Oncol, 1996, 14:2653-2665.
  • 9Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma[J]. Clin Oncol, 1992, 10: 52-60.
  • 10Eggermont AMM. TNF registered in Europe: Does TNF get a second chance? [ J]. J Immunotherapy, 2000, 23: 505-506.

共引文献60

同被引文献61

引证文献9

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部